古塞奇尤单抗显著降低活动性银屑病关节炎急性期蛋白与17型效应细胞因子
基于DISCOVER-1和DISCOVER-2两项3期研究,活动性银屑病关节炎(PsA)患者接受古塞奇尤单抗治疗后,血清CRP、SAA、IL-6、IL-17A、IL-17F和IL-22自第4周起下降并持续至第24周;第24周IL-17A/IL-17F水平与健康对照无显著差异,且IL-17A/IL-17F降幅大于乌司奴单抗。
要点
- 古塞奇尤单抗早期且持续降低PsA患者急性期蛋白与Th17效应细胞因子。
- 第24周IL-17A/IL-17F水平接近健康对照,提示外周IL-23/Th17轴细胞因子正常化。
- IL-17A/IL-17F降幅古塞奇尤单抗大于乌司奴单抗,CRP降幅两者相似。
核心结论
- 古塞奇尤单抗可降低活动性PsA患者血清急性期蛋白和Th17效应细胞因子水平,并使IL-17A/IL-17F达到与健康对照相当的水平。
- 在PsA患者中,古塞奇尤单抗治疗后IL-17A和IL-17F的下降幅度大于乌司奴单抗,而CRP变化两者相似。
研究设计与样本
- 基于DISCOVER-1和DISCOVER-2两项3期研究,PsA患者接受古塞奇尤单抗或安慰剂治疗。
- 在第0、4、24周检测300例受试者及34名健康对照的血清CRP、SAA及炎症细胞因子/趋化因子。
- PSUMMIT研究检测乌司奴单抗治疗后血清IL-17A、IL-17F和CRP,并与古塞奇尤单抗治疗进行比较。
主要发现
- 活动性PsA患者基线血清CRP、SAA、IL-6、IL-17A和IL-17F高于健康对照(p<0.05,几何均值至少高40%)。
- 基线Th17效应细胞因子与基线银屑病显著相关,但与关节疾病活动度无关。
- 与安慰剂相比,古塞奇尤单抗治疗使血清CRP、SAA、IL-6、IL-17A、IL-17F和IL-22最早在第4周下降,并持续下降至第24周(p<0.05,几何均值较基线下降至少33%)。
- 第24周IL-17A和IL-17F水平与健康对照无显著差异,提示治疗后外周IL-23/Th17轴效应细胞因子正常化。
- 古塞奇尤单抗治疗者IL-17A/IL-17F降幅大于乌司奴单抗治疗者,而CRP水平变化相似。
关键数值与推荐
- 活动性PsA患者基线CRP、SAA、IL-6、IL-17A、IL-17F较健康对照升高(p<0.05,几何均值至少高40%)。
- 古塞奇尤单抗较安慰剂使CRP、SAA、IL-6、IL-17A、IL-17F、IL-22下降(p<0.05,几何均值较基线下降至少33%)。
- 第24周IL-17A和IL-17F与健康对照无显著差异。
- 古塞奇尤单抗对IL-17A/IL-17F的降幅大于乌司奴单抗,对CRP的影响相似。
临床怎么用
- 活动性PsA患者基线可见急性期蛋白及Th17效应细胞因子升高,可作为炎症负荷的血清学参考。
- 古塞奇尤单抗治疗早期即可降低CRP、SAA及IL-17A/IL-17F等指标,并持续至第24周。
- IL-17A/IL-17F降幅在古塞奇尤单抗与乌司奴单抗之间存在差异,CRP变化相似,临床解读需结合具体药物。
局限性
- 血清蛋白分析基于DISCOVER-1和DISCOVER-2共300例受试者及34名健康对照,样本量有限。
- 与乌司奴单抗的比较数据来自PSUMMIT研究,非同一研究内的头对头比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate serum protein expression in participants with psoriatic arthritis (PsA) and changes after guselkumab treatment. METHODS: Participants with PsA were treated with guselkumab or placebo in the DISCOVER-1 and DISCOVER-2 studies. Serum levels of acute phase reactants C reactive protein (CRP) and serum amyloid A (SAA) and inflammatory cytokines/chemokines were measured at weeks 0, 4 and 24 in 300 study participants and 34 healthy controls (HCs). The PSUMMIT studies measured serum interleukin (IL)-17A, IL-17F and CRP after ustekinumab treatment and levels with ustekinumab versus guselkumab treatment were compared. RESULTS: Baseline serum levels of CRP, SAA, IL-6, IL-17A and IL-17F were elevated in participants with active PsA vs HCs (p<0.05, geometric mean (GM) ≥40% higher). Baseline T-helper cell 17 (Th17) effector cytokines were significantly associated with baseline psoriasis but not joint disease activity. Compared with placebo, guselkumab treatment resulted in decreases in serum CRP, SAA, IL-6, IL-17A, IL-17F and IL-22 as early as week 4 and continued to decrease through week 24 (p<0.05, GM decrease from baseline ≥33%). At week 24, IL-17A and IL-17F levels were not significantly different from HCs, suggesting normalisation of peripheral IL-23/Th17 axis effector cytokines postguselkumab treatment. Reductions in IL-17A/IL-17F levels were greater in guselkumab-treated versus ustekinumab-treated participants, whereas effects on CRP levels were similar. CONCLUSION: Guselkumab treatment reduced serum protein levels of acute phase and Th17 effector cytokines and achieved comparable levels to those in HCs. In participants with PsA, reductions of IL-17A and IL-17F were of greater magnitude after treatment with guselkumab than with ustekinumab.
引用
- Sweet K, Song Q, Loza MJ, et al. Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials. RMD Open. 2021. PMID: 34011674. doi:10.1136/rmdopen-2021-001679
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。